Run Kirsch is Near, another CETF-funded study that used Remdesivir.
camostat mesilate
The New York Times reported that Kirsch’s COVID Early Treatment Fund (CETF) was funding camostat mesilate trials on May 22, 2020, in addition to hydroxychloroquine and peginterferon lambda.
May 22, 2020. New York Times. Treating Mild Coronavirus Cases Could Help Save Everyone
Only very few treatments are being tested for patients with early-stage symptoms…